Pluristem gets orphan drug designation for PLacental eXpanded cells

02/21/2013 | Globes (Israel)

Pluristem Therapeutics' PLX placental cells have been designated an orphan-disease treatment by the FDA as a therapy for aplastic anemia. "Receiving orphan drug designation for aplastic anemia is an important event for Pluristem as it open pathways for using our PLX cells for additional indications in the field of hematology," said Zami Aberman, Pluristem's chairman and CEO.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL